product summary
Loading...
company name :
Sino Biological
product type :
protein
product name :
SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD (R683A, R685A, F817P, A892P, A899P, A942P, K986P, V987P)-His Recombinant Protein (HPLC-verified)
catalog :
40589-V08H4
quantity :
100 µg
price :
498 USD
more info or order :
Sino Biological product webpage
citations: 27
Reference
Selva K, Lee W, Enriquez A, Aurelia L, Audsley J, Kent H, et al. Elevated SARS-CoV-2 IgG4 in plasma and mucosa following repeated mRNA boosters impact antibody functions to Omicron and sarbecoviruses. EBioMedicine. 2026;123:106087 pubmed publisher
Ma J, Dong X, Yu L, Sun Y, Shi Q. A stable all-D peptide ligand inspires broad-spectrum affinity and high performance in the purification of COVID-19 vaccines. J Chromatogr A. 2026;1766:466577 pubmed publisher
Ganesh P, Prossnitz A, Jons C, Eckman N, Alakesh A, Song Y, et al. Enabling global access to potent subunit vaccines with a simple and scalable injectable hydrogel platform. Biomater Sci. 2026;14:173-185 pubmed publisher
Mak W, Wapperom D, Redel A, Koeleman J, Smit P, Lam Tse W, et al. Seasonal Coronavirus-Induced Immunological Imprinting and Previous Herpesvirus Infections in Patients With Long COVID. J Med Virol. 2025;97:e70582 pubmed publisher
Thompson A, Sankaranarayanan N, Chittum J, Mahida V, Vishweshwara S, Raigawali R, et al. Identification of an Unnatural Sulfated Monosaccharide as a High-Affinity Ligand for Pan-Variant Targeting of SARS-CoV-2 Spike Glycoprotein. ACS Chem Biol. 2025;20:1394-1405 pubmed publisher
Meany E, Klich J, Jons C, Mao T, Chaudhary N, Utz A, et al. Generation of an inflammatory niche in a hydrogel depot through recruitment of key immune cells improves efficacy of mRNA vaccines. Sci Adv. 2025;11:eadr2631 pubmed publisher
F xe9 lix P, Melo A, Costa J, Cola xe7 o M, Pereira D, N xfa xf1 ez J, et al. Exploring TLR agonists as adjuvants for COVID-19 oral vaccines. Vaccine. 2025;53:127078 pubmed publisher
Beavis A, Xiao P, Gingerich M, Briggs K, Li G, Howerth E, et al. A parainfluenza virus 5 (PIV5)-vectored intranasal SARS-CoV-2 vaccine (CVXGA1) elicits protective and long-lasting immunity in nonhuman primates. J Virol. 2025;99:e0199024 pubmed publisher
Tong X, Wang Q, Jung W, Chicz T, Blanc R, Parker L, et al. Compartment-specific antibody correlates of protection to SARS-CoV-2 Omicron in macaques. iScience. 2024;27:110174 pubmed publisher
Jung W, Abdelnour A, Kaplonek P, Herrero R, Shih Lu Lee J, Barbati D, et al. SARS-CoV-2 infection prior to vaccination amplifies Fc-mediated humoral profiles in an age-dependent manner. Cell Rep. 2024;43:114684 pubmed publisher
Ram xed rez M, Loaiza R, Mart xed nez Balboa Y, Bruneau N, Ram xed rez E, Gonz xe1 lez P, et al. Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity. Vaccine. 2024;42:126203 pubmed publisher
Ou B, Baillet J, Filsinger Interrante M, Adamska J, Zhou X, Saouaf O, et al. Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses. Sci Adv. 2024;10:eadn7187 pubmed publisher
Guenthoer J, Garrett M, Lilly M, Depierreux D, Ruiz F, Chi M, et al. The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2. PLoS Pathog. 2024;20:e1012383 pubmed publisher
Meany E, Klich J, Jons C, Mao T, Chaudhary N, Utz A, et al. Generation of an inflammatory niche in an injectable hydrogel depot through recruitment of key immune cells improves efficacy of mRNA vaccines. bioRxiv. 2024;: pubmed publisher
Mayer D, Nelson M, Andriyanova D, Filler R, xd6 kten A, Antao O, et al. A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection. J Control Release. 2024;370:570-582 pubmed publisher
Aydillo T, Balsera Manzanero M, Rojo Fernandez A, Escalera A, Salamanca Rivera C, Pach xf3 n J, et al. Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines. Emerg Microbes Infect. 2024;13:2292068 pubmed publisher
Kehrer T, Cupic A, Ye C, Yildiz S, Bouhaddou M, Crossland N, et al. Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis. Cell Host Microbe. 2023;31:1668-1684.e12 pubmed publisher
Ou B, Baillet J, Filsinger Interrante M, Adamska J, Zhou X, Saouaf O, et al. Saponin Nanoparticle Adjuvants Incorporating Toll-Like Receptor Agonists Improve Vaccine Immunomodulation. bioRxiv. 2023;: pubmed publisher
Tong X, McNamara R, Avenda xf1 o M, Serrano E, Garc xed a Salum T, Pardo Roa C, et al. Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination. Nat Commun. 2023;14:4174 pubmed publisher
Adams L, Leist S, Dinnon K, West A, Gully K, Anderson E, et al. Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination. Cell Rep. 2023;42:112326 pubmed publisher
Park K, Choi A, Kim H, Park I, Eom M, Yeo S, et al. Ultra-sensitive label-free SERS biosensor with high-throughput screened DNA aptamer for universal detection of SARS-CoV-2 variants from clinical samples. Biosens Bioelectron. 2023;228:115202 pubmed publisher
Barber K, Shrock E, Elledge S. CasPlay provides a gRNA-barcoded CRISPR-based display platform for antibody repertoire profiling. Cell Rep Methods. 2022;2:100318 pubmed publisher
Bahnan W, Wrighton S, Sundwall M, Bläckberg A, Larsson O, Höglund U, et al. Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2. Front Immunol. 2021;12:808932 pubmed publisher
Abdillah D, Kereilwe O, Ferdousy R, Saito R, Kadokawa H. Spike protein of SARS-CoV-2 suppresses gonadotrophin secretion from bovine anterior pituitaries. J Reprod Dev. 2022;68:152-159 pubmed publisher
Lin W, Chen I, Chen H, Lee Y, Wu S. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants. Front Immunol. 2021;12:795741 pubmed publisher
Chang X, Zeltins A, Mohsen M, Gharailoo Z, Zha L, Liu X, et al. A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain. Vaccines (Basel). 2021;9: pubmed publisher
Huang J, Wang D, Shipman R, Zhu Z, Liu Y, Li L. Simultaneous enrichment and separation of neutral and sialyl glycopeptides of SARS-CoV-2 spike protein enabled by dual-functionalized Ti-IMAC material. Anal Bioanal Chem. 2021;: pubmed publisher
image
image 1 :
Sino Biological 40589-V08H4 image 1
product information
Catalog Number :
40589-V08H4
Product Name :
SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD (R683A, R685A, F817P, A892P, A899P, A942P, K986P, V987P)-His Recombinant Protein (HPLC-verified)
Product Type :
Protein
Host Species :
HEK293 Cells
Conjugation :
C-His
Size :
100 µg
List Price :
498 USD
Product Description :
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike Protein (S1+S2 ECD) (YP_009724390.1) (Met1-Pro1213(R683A, R685A, F817P, A892P, A899P, A942P, K986P, V987P)) was expressed with the bacteriophage T4 fibritin and a polyhistidine tag at the C-terminus.
SpeciesSummary :
SARS-CoV-2
ALTnames :
Spike,Coronavirus spike
Purity :
> 90 % as determined by SDS-PAGE. > 90 % as determined by SEC-HPLC.
Buffer :
Lyophilized from a sodium citrate buffer system at pH 6.0.
Packaging :
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Storage :
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
more info or order :
Sino Biological product webpage
company information
Sino Biological
Building 9, No.18 Kechuang 10th St, BDA, Beijing, 100176
marketing@sinobiological.com
https://www.sinobiological.com
86 400-890-9989
headquarters: China
Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates.